IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01516294
Recruitment Status : Unknown
Verified October 2012 by Oraya Therapeutics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : January 24, 2012
Last Update Posted : November 1, 2012
Information provided by (Responsible Party):
Oraya Therapeutics, Inc.

Brief Summary:
This study will evaluate the efficacy of IRay treatment in patients with Polypoidal Choroidal Vasculopathy (PCV)secondary to AMD as determined by the change in the proportion of lesion activity and lesion size at 12 months.

Condition or disease Intervention/treatment Phase
Polypoidal Chorodial Vasculopathy Age Related Macular Degeneration Radiation: Iray Not Applicable

Detailed Description:
This is a single-center, interventional clinical trial in which subjects will receive 16 Gy of IRay treatment and Lucentis, followed by Lucentis treatment as needed to evaluate the efficacy of IRay treatment in patients with PCV as determined by the change in the proportion of lesion activity and lesion size at 12 months.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot, Single-center, Interventional Clinical Trial in Which Subjects With Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD) Will Receive Low Voltage Stereotactic Radiotherapy (IRay®) Treatment and Lucentis® Treatment as Needed.
Study Start Date : January 2012
Estimated Primary Completion Date : March 2013
Estimated Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Iray plus Lucentis
open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
Radiation: Iray
The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.

Primary Outcome Measures :
  1. Lesion change as measured with fluorescein angiography. [ Time Frame: Baseline and 12 months ]
    Change in the proportion of the lesion which is active at 12 months.

Secondary Outcome Measures :
  1. Number of Lucentis injections [ Time Frame: baseline and 12 months ]
    Number of Lucentis injections during 12 months

  2. Visual Acuity change [ Time Frame: Baseline and 12 months ]
    Mean change in visual acuity

  3. Polyp changes [ Time Frame: Baseline and 12 months ]
    Change in total lesion and polyp size & number of polyps

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with PCV, naïve or previously treated with Lucentis injections and Photodynamic therapy (PDT) using Visudyne.
  • Must have a total lesion size of <12 disc areas and a PCV lesion with the greatest linear dimension of <6 mm, but not greater than 3 mm from the center of the fovea to the furthest point on lesion perimeter (determined by ICG).
  • The distance from the center of the fovea to the nearest edge of the optic disc should be not less than 3 mm. (This distance is confirmed by Oraya software prior to treatment.).
  • Must have provided informed consent, documented it in writing, and have been given a copy of the signed informed consent form.
  • Must be willing and able to return for scheduled visits for the 2-year duration of the study.
  • Must be at least 50 years of age.
  • Women must be post-menopausal ≥1 year or surgically sterilized, or a pregnancy screen must be performed prior to the study and a reliable form of contraception, approved by the investigator, must be maintained during the study.
  • Must have best corrected visual acuity of 75 to 25 letters (inclusive) in the study eye and at least 20 letters in the fellow eye (if both eyes meet all the study criteria, then the eye with the worst vision should be selected as the study eye).

Exclusion Criteria:

  • CNV due to causes other than AMD or PCV, including ocular histoplasmosis syndrome, angioid streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia (spherical equivalent -8 diopters).
  • A globe axial length of <20 mm or >26 mm.
  • Evidence of diabetes or with retinal findings consistent with diabetic retinopathy or retinopathy for any other cause.
  • Hypertension that is not controlled with anti-hypertensive medication.
  • Prior or concurrent therapies for age related macular degeneration or PCV, including submacular surgery, subfoveal thermal laser photocoagulation (with or without photographic evidence), or transpupillary thermotherapy (TTT).
  • History of radiation to the head in the region of the study eye.
  • Previous posterior vitrectomy at any time, YAG capsulotomy or cataract surgery within 3 months, or any other surgery in the study eye within 6 months prior to the screening visit.
  • Intravitreal device in the study eye.
  • Concomitant disease in the study eye which might interfere with the effect of assessment of the study treatment, including uveitis, acute ocular or periocular infection, retinal vasculopathies (including retinal vein occlusions, etc.) or intraocular pressure >30 mmHg uncontrollable with medications.
  • History of rhegmatogenous retina detachment, optic neuritis or intraocular tumors in the study eye.
  • Inadequate pupillary dilation, significant media opacities, or other conditions in the study eye, including cataract, which may interfere with visual acuity or the evaluation of the posterior segment. Subjects likely to need cataract surgery during the 1 year study period should also not be enrolled.
  • Known serious allergies to fluorescein or indocyanine green dye used in angiography.
  • Subjects must not have subretinal hemorrhage or Retinal Pigment Epithelium tear involving the center of the foveal avascular zone.
  • Known sensitivity or allergy to Lucentis, or any other drug used in the study, such as topical anesthetic, cycloplegic mydriatics, or lubricating eye gel.
  • Contraindication or sensitivity to contact lens application (i.e. corneal dystrophies and recurrent corneal erosions). 16. Currently receiving chemotherapy, having completed a course within the 90 days preceding study enrollment, or expecting to begin chemotherapy while participating in the study.
  • Current participation in another PCV drug or device clinical trial.
  • History of use of drugs with known retinal toxicity, including: chloroquine (Aralen - antimalarial), hydroxychloriquine (Plaquenil - antimalarial), phenothiazines (Thorazine, Stelazine, Mellaril, Prolixin, Trilafon, etc., - tranquilizing antipsychotic medications) and these patients are exhibiting signs of retinal toxicity.
  • Concurrent use of systemic anti-VEGF agents.
  • Any other condition, which in the judgment of the investigator would prevent the subject from granting consent or completing the study, such as dementia, mental illness (including generalized anxiety disorder, claustrophobia, etc.), or inability to position in the device (due to musculoskeletal problems, etc.).
  • History of other significant, uncontrolled disease including cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal, metabolic dysfunction, any clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of intravitreal ranibizumab or that might affect interpretation of the results of the study or render the subject at high risk for treatment complication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01516294

Università Vita-Salute Istituto Scientifico San Raffaele
Milano, Italy
Sponsors and Collaborators
Oraya Therapeutics, Inc.

Responsible Party: Oraya Therapeutics, Inc. Identifier: NCT01516294     History of Changes
Other Study ID Numbers: CLH004
First Posted: January 24, 2012    Key Record Dates
Last Update Posted: November 1, 2012
Last Verified: October 2012

Keywords provided by Oraya Therapeutics, Inc.:

Additional relevant MeSH terms:
Macular Degeneration
Vascular Diseases
Retinal Degeneration
Retinal Diseases
Eye Diseases
Cardiovascular Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents